Mersana Therapeutics, Inc. (MRSN) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
MRSN currently has 4.99M outstanding shares. with minimal authorized share overhang for future dilution. The company has minimally diluted shareholders by 8.04% over the past 2 years. Recent corporate actions include 1 stock split (positive for accessibility) and 1 reverse split (concerning signal).
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Jan 06, 2026 |
POS AM filing: This is a Post-Effective Amendment to terminate the effectiveness of the Registration Statement and remove from registration any and all securities registered but unsold under the Registration Statement due to a merger. |
5M | 0 |
| Nov 14, 2025 |
10-Q filing | 5.0M shares outstanding |
5M | 0 |
| Jul 25, 2025 |
Stock Split
8-K filing: Stock split 1-for-25 | Outstanding: 124,466,113 → 4,978,644 |
5M | 0 |
| May 15, 2025 |
10-Q filing | 124.5M shares outstanding |
120M | 0 |
| Mar 03, 2025 |
10-K filing | 122.5M shares outstanding |
120M | 0 |
| Dec 19, 2024 |
8-K filing: Mersana Therapeutics, Inc. entered into an exchange agreement with EcoR1 Capital, LLC, exchanging 8,036,688 shares of common stock for pre-funded warrants to purchase 8,036,688 shares of common stock, with an exercise price of $0.0001 per share, expected to close on December 20, 2024. |
120M | 0 |
| Nov 13, 2024 |
10-Q filing | 122.7M shares outstanding |
120M | 0 |
| Aug 13, 2024 |
10-Q filing | 122.4M shares outstanding |
120M | 0 |
| May 09, 2024 |
10-Q filing | 121.4M shares outstanding |
120M | 0 |
| Feb 28, 2024 |
POS AM filing: This is an offering of common stock, preferred stock, warrants, and units with an aggregate offering price of up to $300,000,000. |
120M | 0 |
| Feb 28, 2024 |
10-K filing | 116.1M shares outstanding |
120M | 0 |
| Nov 07, 2023 |
10-Q filing | 120.5M shares outstanding |
120M | 0 |
| Sep 06, 2023 |
8-K filing: Appointments of Mohan Bala as Senior Vice President, Chief Development Officer and Ashish Mandelia as Vice President, Chief Accounting Officer, along with RSU grants and board committee reconstitutions were announced. |
120M | 0 |
| Aug 08, 2023 |
10-Q filing | 115.6M shares outstanding |
120M | 0 |
| May 09, 2023 |
10-Q filing | 107.5M shares outstanding |
110M | 0 |
| Feb 28, 2023 |
10-K filing | 108.0M shares outstanding |
110M | 0 |
| Nov 07, 2022 |
10-Q filing | 97.6M shares outstanding |
98M | 0 |
| Aug 08, 2022 |
10-Q filing | 95.8M shares outstanding |
96M | 0 |
| May 09, 2022 |
10-Q filing | 97.0M shares outstanding |
97M | 0 |
| Feb 28, 2022 |
10-K filing | 83.4M shares outstanding |
83M | 0 |
| Nov 09, 2021 |
10-Q filing | 71.8M shares outstanding |
72M | 4.9M |
| Nov 09, 2021 |
S-3 filing: Mersana Therapeutics, Inc. may offer and sell from time to time, in one or more series or issuances and on terms that we will determine at the time of the offering, any combination of the securities described in this prospectus, up to an aggregate amount of $300,000,000. |
70M | 7M |
| Aug 06, 2021 |
10-Q filing | 69.6M shares outstanding |
70M | 0 |
| May 10, 2021 |
10-Q filing | 69.0M shares outstanding |
69M | 0 |
| Feb 26, 2021 |
10-K filing | 69.0M shares outstanding |
69M | 0 |
| Nov 09, 2020 |
10-Q filing | 68.4M shares outstanding |
68M | 0 |
| Aug 07, 2020 |
10-Q filing | 68.4M shares outstanding |
68M | 0 |
| Jun 01, 2020 |
8-K filing: Mersana Therapeutics, Inc. completed a public offering of 8,000,000 shares of common stock at $19.00 per share, with the underwriters exercising their option to purchase an additional 1,200,000 shares at the same price, closing expected on June 2, 2020. |
59M | 0 |
| May 08, 2020 |
10-Q filing | 58.9M shares outstanding |
59M | 0 |
| May 08, 2020 |
S-3 filing: The company is filing an S-3 to offer and sell common stock and preferred stock, up to an aggregate amount of $250,000,000 from time to time. |
59M | 0 |
| Feb 28, 2020 |
10-K filing | 45.4M shares outstanding |
45M | 0 |